Boron supplementation and activated factor VII in healthy men

JMW Wallace, MPA Hannon-Fletcher, PJ Robson, WS Gilmore, SA Hubbard, JJ Strain

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: The aim of the present study was to determine whether postprandial concentrations of the active component of serine protease coagulation factor VII (Vila) were lowered by acute boron supplementation in vivo. Design: An acute, randomized, placebo-controlled, double blind, cross-over study. Setting: Free-living population. Subjects: Fifteen apparently healthy men, aged 45-65y. Interventions: Subjects visited the Centre on two occasions, with the study days separated by a minimum of 2 weeks. Following collection of a fasting blood sample, subjects received either placebo or acute bolus of 11.6mg boron (given as 102.6mg sodium tetraborate decahydrate) together with a standard fat-rich meal. Blood samples were obtained at 1, 2, 4 and 6 h after the administration of the test meal, during which time subjects were at liberty to consume deionized water only. Blood samples were assayed for concentrations of insulin, glucose, lipids and boron. Measurement of the concentration of activated factor Vila and of factor VII antigen, and of the activity of coagulation factors VII, IX and X was also carried out. Results: Plasma boron concentrations were significantly higher following consumption of the boron supplement compared with placebo (0.124+/-0.02 vs 0.008+/-0.01 mg/l; Pless than or equal to0.001). There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile. Factor Vila rose significantly following consumption of the high fat meal (1.05+/-0.07 vs 1.26+/-0.07; Pless than or equal to0.001), but this increase was not altered by boron supplementation. Conclusions: Results from this study suggest that acute boron supplementation (at 11.6 mg boron) does not alter the activity of factor Vila following consumption of a high-fat meal. Sponsorship: This work was funded by Borax Europe Ltd.
LanguageEnglish
Pages1102-1107
JournalEuropean Journal of Clinical Nutrition
Volume56
Issue number11
Publication statusPublished - Nov 2002

Fingerprint

Factor VIIa
Boron
Factor VII
Meals
Fats
Placebos
Insulin
Lipids
Glucose
Factor X
Factor IX
Blood Coagulation Factors
Serine Proteases
Cross-Over Studies
Fasting
Antigens
Water

Cite this

Wallace, JMW ; Hannon-Fletcher, MPA ; Robson, PJ ; Gilmore, WS ; Hubbard, SA ; Strain, JJ. / Boron supplementation and activated factor VII in healthy men. In: European Journal of Clinical Nutrition. 2002 ; Vol. 56, No. 11. pp. 1102-1107.
@article{bb27f4f90d37494ca084c1c1b0ee4b0e,
title = "Boron supplementation and activated factor VII in healthy men",
abstract = "Objective: The aim of the present study was to determine whether postprandial concentrations of the active component of serine protease coagulation factor VII (Vila) were lowered by acute boron supplementation in vivo. Design: An acute, randomized, placebo-controlled, double blind, cross-over study. Setting: Free-living population. Subjects: Fifteen apparently healthy men, aged 45-65y. Interventions: Subjects visited the Centre on two occasions, with the study days separated by a minimum of 2 weeks. Following collection of a fasting blood sample, subjects received either placebo or acute bolus of 11.6mg boron (given as 102.6mg sodium tetraborate decahydrate) together with a standard fat-rich meal. Blood samples were obtained at 1, 2, 4 and 6 h after the administration of the test meal, during which time subjects were at liberty to consume deionized water only. Blood samples were assayed for concentrations of insulin, glucose, lipids and boron. Measurement of the concentration of activated factor Vila and of factor VII antigen, and of the activity of coagulation factors VII, IX and X was also carried out. Results: Plasma boron concentrations were significantly higher following consumption of the boron supplement compared with placebo (0.124+/-0.02 vs 0.008+/-0.01 mg/l; Pless than or equal to0.001). There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile. Factor Vila rose significantly following consumption of the high fat meal (1.05+/-0.07 vs 1.26+/-0.07; Pless than or equal to0.001), but this increase was not altered by boron supplementation. Conclusions: Results from this study suggest that acute boron supplementation (at 11.6 mg boron) does not alter the activity of factor Vila following consumption of a high-fat meal. Sponsorship: This work was funded by Borax Europe Ltd.",
author = "JMW Wallace and MPA Hannon-Fletcher and PJ Robson and WS Gilmore and SA Hubbard and JJ Strain",
year = "2002",
month = "11",
language = "English",
volume = "56",
pages = "1102--1107",
journal = "European Journal of Clinical Nutrition",
issn = "0954-3007",
number = "11",

}

Wallace, JMW, Hannon-Fletcher, MPA, Robson, PJ, Gilmore, WS, Hubbard, SA & Strain, JJ 2002, 'Boron supplementation and activated factor VII in healthy men', European Journal of Clinical Nutrition, vol. 56, no. 11, pp. 1102-1107.

Boron supplementation and activated factor VII in healthy men. / Wallace, JMW; Hannon-Fletcher, MPA; Robson, PJ; Gilmore, WS; Hubbard, SA; Strain, JJ.

In: European Journal of Clinical Nutrition, Vol. 56, No. 11, 11.2002, p. 1102-1107.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Boron supplementation and activated factor VII in healthy men

AU - Wallace, JMW

AU - Hannon-Fletcher, MPA

AU - Robson, PJ

AU - Gilmore, WS

AU - Hubbard, SA

AU - Strain, JJ

PY - 2002/11

Y1 - 2002/11

N2 - Objective: The aim of the present study was to determine whether postprandial concentrations of the active component of serine protease coagulation factor VII (Vila) were lowered by acute boron supplementation in vivo. Design: An acute, randomized, placebo-controlled, double blind, cross-over study. Setting: Free-living population. Subjects: Fifteen apparently healthy men, aged 45-65y. Interventions: Subjects visited the Centre on two occasions, with the study days separated by a minimum of 2 weeks. Following collection of a fasting blood sample, subjects received either placebo or acute bolus of 11.6mg boron (given as 102.6mg sodium tetraborate decahydrate) together with a standard fat-rich meal. Blood samples were obtained at 1, 2, 4 and 6 h after the administration of the test meal, during which time subjects were at liberty to consume deionized water only. Blood samples were assayed for concentrations of insulin, glucose, lipids and boron. Measurement of the concentration of activated factor Vila and of factor VII antigen, and of the activity of coagulation factors VII, IX and X was also carried out. Results: Plasma boron concentrations were significantly higher following consumption of the boron supplement compared with placebo (0.124+/-0.02 vs 0.008+/-0.01 mg/l; Pless than or equal to0.001). There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile. Factor Vila rose significantly following consumption of the high fat meal (1.05+/-0.07 vs 1.26+/-0.07; Pless than or equal to0.001), but this increase was not altered by boron supplementation. Conclusions: Results from this study suggest that acute boron supplementation (at 11.6 mg boron) does not alter the activity of factor Vila following consumption of a high-fat meal. Sponsorship: This work was funded by Borax Europe Ltd.

AB - Objective: The aim of the present study was to determine whether postprandial concentrations of the active component of serine protease coagulation factor VII (Vila) were lowered by acute boron supplementation in vivo. Design: An acute, randomized, placebo-controlled, double blind, cross-over study. Setting: Free-living population. Subjects: Fifteen apparently healthy men, aged 45-65y. Interventions: Subjects visited the Centre on two occasions, with the study days separated by a minimum of 2 weeks. Following collection of a fasting blood sample, subjects received either placebo or acute bolus of 11.6mg boron (given as 102.6mg sodium tetraborate decahydrate) together with a standard fat-rich meal. Blood samples were obtained at 1, 2, 4 and 6 h after the administration of the test meal, during which time subjects were at liberty to consume deionized water only. Blood samples were assayed for concentrations of insulin, glucose, lipids and boron. Measurement of the concentration of activated factor Vila and of factor VII antigen, and of the activity of coagulation factors VII, IX and X was also carried out. Results: Plasma boron concentrations were significantly higher following consumption of the boron supplement compared with placebo (0.124+/-0.02 vs 0.008+/-0.01 mg/l; Pless than or equal to0.001). There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile. Factor Vila rose significantly following consumption of the high fat meal (1.05+/-0.07 vs 1.26+/-0.07; Pless than or equal to0.001), but this increase was not altered by boron supplementation. Conclusions: Results from this study suggest that acute boron supplementation (at 11.6 mg boron) does not alter the activity of factor Vila following consumption of a high-fat meal. Sponsorship: This work was funded by Borax Europe Ltd.

M3 - Article

VL - 56

SP - 1102

EP - 1107

JO - European Journal of Clinical Nutrition

T2 - European Journal of Clinical Nutrition

JF - European Journal of Clinical Nutrition

SN - 0954-3007

IS - 11

ER -